Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26644
Abstract: Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical trials in dialysis‐dependent and non–dialysis‐dependent… read more here.
Keywords: anemia associated; chronic kidney; alfa; kidney disease ... See more keywords
Successful perinatal management of a dichorionic diamniotic twin pregnancy in an anaemic kidney transplant patient treated with Darbepoetin alfa: a case report
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Obstetrics and Gynaecology"
DOI: 10.1080/01443615.2019.1636776
Abstract: A 33-year-old female received a living-related kidney transplant from her mother following haemodialysis for one year due to chronic renal failure owing to a congenital dysplastic kidney disease at the age of 13 years. The… read more here.
Keywords: level; darbepoetin alfa; week gestation; haemoglobin level ... See more keywords
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab085.0022
Abstract: The Anemia Study in Chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor (PHI) Daprodustat-Non-Dialysis (ASCEND-ND; NCT02876835) trial is evaluating the efficacy and safety of daprodustat when compared with darbepoetin alfa in CKD… read more here.
Keywords: darbepoetin alfa; study; daprodustat; baseline characteristics ... See more keywords
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13609
Abstract: Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat may be beneficial for patients who inadequately respond to erythropoiesis‐stimulating agents… read more here.
Keywords: eri; treatment; roxadustat darbepoetin; darbepoetin alfa ... See more keywords
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0231830
Abstract: Renal anemia is predominantly caused by a relative deficiency in erythropoietin (EPO). Conventional treatment for renal anemia includes the use of recombinant human EPO (rhEPO) or a long-acting erythropoiesis-activating agent named darbepoetin alfa, which is… read more here.
Keywords: long acting; darbepoetin alfa; darbepoetin; erythropoiesis ... See more keywords
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2019060623
Abstract: BACKGROUND Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemia.… read more here.
Keywords: study; darbepoetin alfa; ckd; darbepoetin ... See more keywords